SCHEMBL5656119

SCHEMBL5656119

CCOc1ccccc1NC(=O)OCCCN1CCN(c2ccccc2F)CC1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.61
CYP2C9 P11712 3/20 0.56
CYP2C19 P33261 3/20 0.56
KMT2A Q03164 2/20 0.56
NPSR1 Q6W5P4 2/20 0.56
CYP1A2 P05177 2/20 0.56
MEN1 O00255 1/20 0.56
MAPT P10636 2/20 0.55
TP53 P04637 1/20 0.55
CYP2D6 P10635 2/20 0.53
LMNA P02545 1/20 0.52
ADRA1D P25100 2/20 0.52
ADRA1A P35348 2/20 0.52
ADRA1B P35368 2/20 0.52
MAPK1 P28482 1/20 0.50
ALDH1A1 P00352 2/20 0.49
TSHR P16473 1/20 0.49
HSD17B10 Q99714 1/20 0.49
ALOX15 P16050 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5657858 0.94 PKM (0.63) PKMCYP2C9CYP2C19KMT2ANPSR1
SCHEMBL5655966 0.90 NPSR1 (0.69) CYP2C9CYP2C19KMT2ANPSR1CYP1A2
SCHEMBL5655907 0.89 ADRA1D (0.53) LMNAADRA1DADRA1AADRA1B
SCHEMBL5654887 0.89 ADRA1A (0.66) KMT2AMEN1ADRA1DADRA1AADRA1B
SCHEMBL5657076 0.89 ADRA1D (0.53) KMT2AMAPTLMNAADRA1DADRA1A
SCHEMBL5656051 0.87 MAPT (0.56) KMT2AMEN1MAPTTP53ALOX15
SCHEMBL5655895 0.85 MEN1 (0.57) KMT2ANPSR1MEN1MAPTTP53
SCHEMBL5657183 0.84 DRD2 (0.55) ADRA1DADRA1AADRA1B
SCHEMBL5654961 0.84 NPSR1 (0.72) CYP2C9CYP2C19KMT2ANPSR1CYP1A2
SCHEMBL5655836 0.83 GAA (0.50) KMT2ANPSR1MAPTLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238693-B2 Aryl carbamate derivatives, preparation and use thereof CEREP (FR) 2007-07-03 US disclosed
US-7238693-B2 Aryl carbamate derivatives, preparation and use thereof CEREP (FR) 2007-07-03 US disclosed
US-7238693-B2 Aryl carbamate derivatives, preparation and use thereof CEREP (FR) 2007-07-03 US disclosed
US-20040058933-A1 Aryl carbamate derivatives, preperation and use thereof CEREP (FR) 2004-03-25 US disclosed
EP-1362041-A1 ARYL CARBAMATE DERIVATIVES, PREPARATION AND USE THEREOF Cerep (FR) 2003-11-19 EP disclosed
WO-2002068399-A1 ARYL CARBAMATE DERIVATIVES, PREPARATION AND USE THEREOF CEREP (FR) 2002-09-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058933-A1 Aryl carbamate derivatives, preperation and use thereof HTR4, HTR5A, HTR3C PKM 1446/4885CYP2C9 97/4885CYP2C19 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.